• Editorial Board

    May 21, 2026, 11:08

  • International Reference Pricing: Impact of Changing the Basket of Reference Countries on Ability to Reference and on Drug Launch Prices in 6 Markets

    May 1, 2026, 00:00

  • Technological Maturity and Cost-Effectiveness of Medical Artificial Intelligence: A Systematic Review of Health Economic Evaluations

    May 1, 2026, 00:00

  • Assessing the Role of Presurgical Information on Patient-Reported Outcomes: A Causal Analysis

    May 1, 2026, 00:00

  • Switching From EQ-5D-3L to EQ-5D-5L in England: The Impact in NICE Technology Appraisals

    May 1, 2026, 00:00

  • From Prediction to Optimization: Machine Learning-Driven Integration of the Health Economic Value Chain and Revolution in System Efficiency

    May 1, 2026, 00:00

  • Welfare-Based Healthcare Planning: Methodology and Application to Thoracic Surgical Treatment of Lung Cancer in Germany

    May 1, 2026, 00:00

  • Estimating the Global Macroeconomic Impact of Tuberculosis Among Children and Adolescents

    May 1, 2026, 00:00

  • Influence of Initial Imaging Modality on Peri-Diagnostic Outcomes Among Pancreatic, Liver, Ovarian, and Bladder Cancers Without Routine Screening Programs: A Surveillance, Epidemiology, and End Results-Medicare Study

    May 1, 2026, 00:00

  • A Practical Method for Estimating Generalized Risk-Adjusted Cost-Effectiveness Utilities and Willingness-to-Pay Corrections

    May 1, 2026, 00:00

  • The Dark Side of the “Thousand-Faces” Vision: Ethical and Economic Reflections on Algorithmic Psychotherapy Matching

    May 1, 2026, 00:00

  • Author Reply

    May 1, 2026, 00:00

  • Applying the Argument-Based Approach to Validation With Clinical Outcome Assessments: Strategies for Constructing a Rationale

    May 1, 2026, 00:00

  • No Differential Item Functioning of Patient-Reported Outcomes Measurement Information System Global Health Items by Neighborhood Socioeconomic Deprivation

    May 1, 2026, 00:00

  • Valuing Child Health: An EQ-5D-Y-3L Value Set for the United States

    May 1, 2026, 00:00

  • Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force

    May 1, 2026, 00:00

  • Accounting for the Scarcity of Time as Patients Approach End of Life: The Construction of End-Weighted Time Toxicity

    May 1, 2026, 00:00

  • Uncovering the Cost-Effectiveness of Theory-Based Implementation Approaches: A Health Economic Analysis of the Hide and Seek Project Trial

    May 1, 2026, 00:00

  • Development of a Brief Personal Health Agency Measure Among Patients Seeking Discretionary Musculoskeletal Specialty Care

    May 1, 2026, 00:00

  • Estimating Heterogeneous Treatment Effects With Real-World Health Data: A Scoping Review of Machine Learning Methods

    May 1, 2026, 00:00

  • Optimizing Decision Making in Universal Newborn Hearing Screening: A Value of Information Perspective

    May 1, 2026, 00:00

  • Syringe Services Participants’ Preferences for Wound Care, HIV/Hepatitis C Virus Screening, and Opioid Use Disorder Treatment: A Discrete Choice Experiment

    May 1, 2026, 00:00

  • A United Kingdom Value Set for the EQ-5D-5L

    May 1, 2026, 00:00

  • Preferences for Neurodevelopmental Screening Modalities for Children: A Labeled Discrete Choice Experiment Using Partial Choice Set Design

    May 1, 2026, 00:00

  • Table of Contents

    May 1, 2026, 00:00

  • Editorial Board

    Apr 6, 2026, 13:15

  • Evaluation of Health Technology Assessment Frameworks for In Vivo Diagnostics: Assessing Methodological Gaps and Implications for Market Access

    Apr 1, 2026, 00:00

  • Valuing Pediatric Technologies: A Framework for Parental Spillovers in Spinal Muscular Atrophy Bereavement

    Apr 1, 2026, 00:00

  • Economic Evaluations of Orphan Drugs for Rare Kidney Diseases in Low- and Middle-Income Countries: A Bibliometric Systematic Review With Policy and Evidence Gaps Analysis

    Apr 1, 2026, 00:00

  • Face Validation of an Artificial Intelligence Driven Tool for Clinical Triaging in Australian Public Oral Healthcare: A Pilot Study

    Apr 1, 2026, 00:00

  • A Forward Agenda for Digital Health Technologies: Evidence That Works for Decisions

    Apr 1, 2026, 00:00

  • Decision Analytic Models to Assess the Cost-Effectiveness of Prevention, Detection, and Treatment in Multiple Long-Term Conditions: A Scoping Review

    Apr 1, 2026, 00:00

  • Impact of Heatwaves on Health-Related Quality of Life in Older Chinese Adults: A Longitudinal Cohort Study

    Apr 1, 2026, 00:00

  • From Consensus to Implementation: Advancing Patient-Centered Health Technology Assessment

    Apr 1, 2026, 00:00

  • Author Reply

    Apr 1, 2026, 00:00

  • Author Reply

    Apr 1, 2026, 00:00

  • Cost Savings and Improved Clinical Outcomes From a Mobile Health Cardiovascular Disease Self-Management Program

    Apr 1, 2026, 00:00

  • Toward a Harmonized Health Technology Assessment Framework for Digital Health Technologies in Europe

    Apr 1, 2026, 00:00

  • How Good Is Good Enough? A Simulation Study of Adaptive Health Technology Assessment

    Apr 1, 2026, 00:00

  • Valuing Child and Adolescent Health States to Derive Utilities for Use in Economic Evaluation: A Good Practices Report of an ISPOR Task Force

    Apr 1, 2026, 00:00

  • Estimating the Shares of the Value of Branded Pharmaceuticals Accruing to Manufacturers and to Patients in the Thai Healthcare System

    Apr 1, 2026, 00:00

  • Table of Contents

    Apr 1, 2026, 00:00

  • Deepening and Broadening: Revisiting Theories, Long-Term Economic Impact, and Diversity in Parental Bereavement After the Loss of a Child to Spinal Muscular Atrophy

    Apr 1, 2026, 00:00

  • A Patient-Level Simulation Tool to Inform Data-Driven Pain Treatment Decisions and Policy in the US Military Health System

    Apr 1, 2026, 00:00

  • The Effect of Perspective, Duration, and Views on Death on the Valuation of Severe Health States

    Apr 1, 2026, 00:00

  • A Systematic Review of the Methods and Quality of Economic Evaluations for Artificial-Intelligence-Assisted Cancer Screening or Diagnosis

    Apr 1, 2026, 00:00

  • Qini Curves for Potential Impact Assessment of Risk Predictive Models Informing Intervention Policies

    Apr 1, 2026, 00:00

  • Implications of Incorporating Environmental Sustainability Into Health Technology Assessment for Digital Health Technologies

    Apr 1, 2026, 00:00

  • Reanalyzing Value Assessments in American Heart Association Clinical Practice Guidelines Using Health Years in Total Instead of Quality-Adjusted Life-Years

    Apr 1, 2026, 00:00

  • System-Wide Use of Patient-Reported Outcome Measures in Organization for Economic Co-operation and Development Countries: Insights From a Health Policy Survey and Key Informant Workshops

    Apr 1, 2026, 00:00

  • Exploring Methods to Include Carbon Emissions Into a Health Technology Assessment: The Case of Remote Patient Monitoring

    Apr 1, 2026, 00:00

  • Editorial Board

    Mar 11, 2026, 10:20

  • Table of Contents

    Mar 1, 2026, 00:00

  • Psychometric Performance of Skin, Self-Confidence, and Social Health-Related EQ-5D-5L Bolt-Ons in Patients With Atopic Dermatitis and Psoriasis in Germany

    Mar 1, 2026, 00:00

  • Author Reply

    Mar 1, 2026, 00:00

  • Comparative Responsiveness of Preference-Based Health-Related Quality of Life, Social Care, and Well-Being Measures in the Context of Multiple Sclerosis

    Mar 1, 2026, 00:00

  • Comparative Effectiveness of Ixekizumab Versus Ustekinumab in Patients With Psoriasis: A Randomized Controlled Trial Replication Using Data From an Observational Study (Shanghai Psoriasis Effectiveness Evaluation Cohort)

    Mar 1, 2026, 00:00

  • Return-on-Investment in Health Economic Evaluation: An Exploratory Analysis

    Mar 1, 2026, 00:00

  • Quantifying Accuracy and Cost in Public Preferences for Artificial Intelligence in Radiation Therapy

    Mar 1, 2026, 00:00

  • The Uneven Path of Psychological Distress: How Socioeconomic Status Shapes Distress Transitions in Australian Adults

    Mar 1, 2026, 00:00

  • Economic Evaluation of Deprescribing in Older Adults: A Systematic Review

    Mar 1, 2026, 00:00

  • The Compounding Burden of Pregnancy Loss: A Longitudinal Analysis of Quality-of-Life Trajectories After Miscarriage

    Mar 1, 2026, 00:00

  • Genomic Testing in Australia: A Budget Impact Analysis Using Diffusion Modeling From a Healthcare System Perspective

    Mar 1, 2026, 00:00

  • Patient-Reported Outcome Measures in Clinical Trials: An Analysis of Trends From 2008 to 2023

    Mar 1, 2026, 00:00

  • Priority for Self or Others? Incorporating Equity Considerations in a Preference-Based Health Value Assessment

    Mar 1, 2026, 00:00

  • Empirical Evidence and Conceptual Framework to Address the Indian Health Service Underfunding Challenge

    Mar 1, 2026, 00:00

  • Psychometric Properties of Cognition Bolt-Ons for the EQ-5D-3L and EQ-5D-5L: A Systematic Review

    Mar 1, 2026, 00:00

  • Estimating the Willingness-to-Pay per Quality-Adjusted Life-Year to Aid Health Technology Assessment in India

    Mar 1, 2026, 00:00

  • Health Utility Decrements Associated With Social Isolation and Loneliness: Evidence From Australian Longitudinal Data

    Mar 1, 2026, 00:00

  • Impact of China’s National Drug Price Negotiation Policy on Availability, Affordability, and Regional Equity of Negotiated Drugs: A Multidimensional Nationwide Analysis, 2018 to 2021

    Mar 1, 2026, 00:00

  • Disinvestment and Health Spending Efficiency in Latin America and the Caribbean: A Case Study of Colombia

    Mar 1, 2026, 00:00

  • Evaluating Long-Term Health Disparity Impacts of Clinical Algorithms Using a Patient-Level Simulation Framework

    Mar 1, 2026, 00:00

  • Reversing Proxy Roles: Care Recipients as Proxies for Caregiver Health-Related Quality of Life

    Mar 1, 2026, 00:00

  • A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making

    Feb 1, 2026, 00:00

  • Development of a Preference Weighting System for the Parent-Proxy Child Chronic Cough Quality-of-Life Instrument

    Feb 1, 2026, 00:00

  • What Costs and Benefits Should be Counted in Health Technology Assessments and Guidelines? The NICE Perspective

    Feb 1, 2026, 00:00

  • Preferences for Adopting Artificial Intelligence in Radiation Therapy Treatment: A Discrete Choice Experiment

    Feb 1, 2026, 00:00

  • Long-Term Outcomes and Cost-Effectiveness of Artificial Intelligence for Breast Cancer Screening: A Modeling Study

    Feb 1, 2026, 00:00

  • Mapping Methodologies for Economic Evaluation of Digital Health Technologies: A Scoping Review

    Feb 1, 2026, 00:00

  • The Cost-Effectiveness of Community Health Workers in Primary Health Care: A Systematic Review

    Feb 1, 2026, 00:00

  • Means Can Be Deceiving: Comparing and Contrasting Risk Tolerance Estimates From a Discrete-Choice Experiment and a Threshold Technique Exercise

    Feb 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children With Asthma

    Feb 1, 2026, 00:00

  • Comparing Psychometric Properties of 6 of the 5-Level and 3-Level EQ-5D Bolt-Ons in a Large, Multinational, Longitudinal General Population Sample

    Feb 1, 2026, 00:00

  • Research Method, Conduct, and Reporting Considerations for Improving the Quality of Non-Hypothesis-Evaluating Treatment Effectiveness Analyses Using Real-World Data: An ISPOR Special Interest Group Report

    Feb 1, 2026, 00:00

  • Cost-Effectiveness of Reorganizing the Approach to Diabetes Through the Application of Registries: An Innovative Model to Organize Diabetes Care in First Nations Communities in Canada

    Feb 1, 2026, 00:00

  • Should Early-Stage NIH Funding Influence Pharmaceutical Drug Pricing?

    Feb 1, 2026, 00:00

  • How Do Different Health States Impact Preferences for Social-Care-Related Quality of Life: An Exploration of EQ-5D-5L and Adult Social Care Outcomes Toolkit Using a Vignette Approach

    Feb 1, 2026, 00:00

  • Derivation of Meaningful Change Thresholds for European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-LC13 in Patients With Small-Cell Lung Cancer

    Feb 1, 2026, 00:00

  • EQ-5D-5L in Multiple Sclerosis: Estimated Utility Values, Minimal (Clinically) Important Changes, and Direct and Indirect Influences Over Time

    Feb 1, 2026, 00:00

  • Mental Health, Quality of Life, and Work Functioning of Parents of Children Who Have Died of Spinal Muscular Atrophy

    Feb 1, 2026, 00:00

  • PROM-ising Progress? Trends in Patient- and Clinician-Reported Outcome Measures in US Food and Drug Administration Orphan Drug Labels

    Feb 1, 2026, 00:00

  • Hospital and Regional-Level Factors Associated With Negotiated Payer Rates for Hip Fracture Fixation: A Multistate Analysis

    Feb 1, 2026, 00:00

  • Editorial Board

    Jan 23, 2026, 08:45

  • Table of Contents

    Jan 23, 2026, 08:41

  • Table of Contents

    Jan 5, 2026, 12:03

  • Comparing Adolescent and Adult Preferences for EQ-5D-Y-3L Health States in Hong Kong

    Jan 1, 2026, 00:00

  • Combining Simulation Model-Based Outcomes With County-Level Data for Geographic Health Equity Impact Evaluations of New Interventions

    Jan 1, 2026, 00:00

  • Editorial Board

    Jan 1, 2026, 00:00

  • Unlocking Patient Preferences: The Potential of Stated-Preference Methods in Clinical Decision Making

    Jan 1, 2026, 00:00

  • Implications of Value Set Choice on EQ-5D-Y-3L Child and Proxy Health-Related Quality of Life Ratings: What to Do When a Country-Specific “Y” Value Set Is Unavailable?

    Jan 1, 2026, 00:00

  • Toward a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report

    Jan 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children Aged 8 to 18 Years With Eczema

    Jan 1, 2026, 00:00

  • Predicting Healthcare Utilization Outcomes With Artificial Intelligence: A Large Scoping Review

    Jan 1, 2026, 00:00

  • The Cost-Effectiveness of Collagenase Injection Versus Limited Fasciectomy for Moderate Dupuytren’s Contracture: An Economic Evaluation of the Dupuytren’s Interventions Surgery Versus Collagenase Trial and a Decision Analytical Model

    Jan 1, 2026, 00:00

  • Operationalizing Distributional Cost-Effectiveness in Genomic Medicine: A United States–Focused Comment

    Jan 1, 2026, 00:00

  • Clinical Outcomes and Measures for Vaginal Relaxation Syndrome: A Systematic Review

    Jan 1, 2026, 00:00

  • Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation Program

    Jan 1, 2026, 00:00

  • Incorporating Informal Caregiving Time Into Cost-Effectiveness Analysis for Adults Aged 50 and Older: Estimating From Health-Related Quality of Life and Functional Status

    Jan 1, 2026, 00:00

  • Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds

    Jan 1, 2026, 00:00

  • Health Inequality Aversion in the United States

    Jan 1, 2026, 00:00

  • Methodological Insights From Health Valuation Studies in Low- and Middle-Income Countries: A Scoping Review

    Jan 1, 2026, 00:00

  • Integrating Price Benchmarks and Comparative Clinical Effectiveness to Predict Initial Price Offers for Medicare Drug Price Negotiation (Initial Price Applicability Year 2027)

    Jan 1, 2026, 00:00

  • Adult Social Care Outcomes Toolkit and ICEpop Capability Measure in Decision Making: A Review of NICE Social Care and Public Health Guidelines

    Jan 1, 2026, 00:00

  • A Generalized Risk-Adjusted Cost-Effectiveness Economic Model for Measuring the Value of Interventions That Delay Mobility Impairment Across Neurological Conditions

    Jan 1, 2026, 00:00

  • Application of International Reference Pricing Rules to Forecast Pharmaceutical Launch Prices in 5 European Countries

    Jan 1, 2026, 00:00

  • Disclaimer

    Dec 19, 2025, 11:50

  • Editorial Board

    Dec 16, 2025, 09:49

  • HTA262 Overall Survival Adjusted for Subsequent Treatments: A Review of Health Technology Assessments

    Dec 1, 2025, 00:00

  • PCR84 Evaluating the Role of Patient-Reported Outcomes in Phase 4 Clinical Trials: Trends, Applications, and Implications for Postmarketing Surveillance

    Dec 1, 2025, 00:00

  • RWD142 Real-World Healthcare Resource Utilization and Costs Associated With Malignant Brain Tumors in the Brazilian Private Market

    Dec 1, 2025, 00:00

  • EPH34 Burden of Hospitalized Viral Respiratory Infections in Fran Insights From the 2022-2023 Season

    Dec 1, 2025, 00:00

  • EE69 Assessment of the Economic and Societal Impact of Cervical Cancer Treatment in Bulgaria

    Dec 1, 2025, 00:00

  • EE737 Treatment Patterns of Rare Immunodeficiencies With Special Regard to Antibiotics: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • EPH184 Prediabetes Prevalence and Progression in the UAE: Insights for Early Intervention and Resource Optimization

    Dec 1, 2025, 00:00

  • EE125 Climate Impact of CAR-T Cell Therapy in the Netherlands: A Comparison on the Use Phase Emission Between Standard of Care and CAR-T Cell Therapy in Hemato-oncology

    Dec 1, 2025, 00:00

  • HTA19 Accounting for Bereavement in NICE Pediatric Health Technology Appraisals: A Review of the Inclusion of Caregiver Health Utilities After the Death of a Child

    Dec 1, 2025, 00:00

  • MSR2 A Disease Progression Model Comparing Respiratory and Motor Decline in People With Late-Onset Pompe Disease Treated With Cipaglucosidase Alfa Plus Miglustat vs. Alglucosidase Alfa

    Dec 1, 2025, 00:00

  • HTA110 Differences in the Reimbursement Pathway for Ultraorphan Therapies in England and Ireland

    Dec 1, 2025, 00:00

  • CO195 Qualitative Exit Interviews in Charcot-Marie-Tooth Type-2 Sorbitol Dehydrogenase (CMT-SORD) Deficiency

    Dec 1, 2025, 00:00

  • RWD186 Trends of Prescriptions for Medical Technologies Not Covered by the Colombian Health Benefits Package Between 2020 and 2024: A Descriptive Study

    Dec 1, 2025, 00:00

  • HPR5 A Comparative Analysis of Similarities and Differences of RWE Standards Across Regulatory and Health Technology Assessment Bodies

    Dec 1, 2025, 00:00

  • SA88 Systematic Literature Review on the Burden and Economic Impact of Invasive Meningococcal Disease in Adolescents and Young Adults in France, Italy, Spain, and Germany

    Dec 1, 2025, 00:00

  • HTA146 Exploring Nordic Real-World Evidence Sources for a PICO Assessment of a Hypothetical Oncology Drug and Medical Device Product

    Dec 1, 2025, 00:00

  • HTA326 The Phantom Mena How Consultations and Appeals During NICE HST Appraisals Contribute to Delays in Patient Access

    Dec 1, 2025, 00:00

  • CO16 Assessing the Real-World Impact of Earlier Initiation of Anti-Tumor Necrosis Factor vs. Conventional Synthetic DMARDs on Clinical and Patient-Reported Outcomes in Patients With Rheumatoid Arthritis in Europe

    Dec 1, 2025, 00:00

  • CO238 The Clinical Impact of Screening Blood Donations for Hepatitis E Virus in Catalonia

    Dec 1, 2025, 00:00

  • HPR164 Prices And Reimbursement Conditions for Poly (ADP-RIBOSE) Polymerase Inhibitors (PARPi) Indicated for Ovarian Cancer in Spain

    Dec 1, 2025, 00:00

  • EE336 Discrete Event Simulation and Treatment Sequencing Cost-Effectiveness Model in Second-Line Highly Active Relapse Remitting Multiple Sclerosis for a NICE Multiple Technology Appraisal

    Dec 1, 2025, 00:00

  • EE133 Clinical Management and Outcomes of Patients in England With eGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Observational Study and Its Impact on UK Health Technology Assessments

    Dec 1, 2025, 00:00

  • PCR80 Evaluating Migration Errors in COA: Development and Validation of the IQVIA Migration Error Severity Scale (I-MESS)

    Dec 1, 2025, 00:00

  • EE159 Cost Comparison of Symptom Treatment in Atopic Dermatitis Using Upadacitinib and Dupilumab in Poland

    Dec 1, 2025, 00:00

  • PCR82 Evaluating the Feasibility and Acceptability of a Personalized Endpoint: A Prospective Mixed Methods Study of Inventory-Facilitated Goal Attainment Scaling

    Dec 1, 2025, 00:00

  • HTA339 Transparency Tested: Conflict of Interest in EU HTA

    Dec 1, 2025, 00:00

  • EPH39 Changes in the Epidemiological Indicators of Female Infertility in Europe 1991-2021

    Dec 1, 2025, 00:00

  • EE726 The Socioeconomic Value of Adult Respiratory Immunization Programs in Fran Can Improved Coverage Unlock Missed Gains?

    Dec 1, 2025, 00:00

  • EE243 Cost-Effectiveness of Control-IQ Hybrid Closed-Loop System in Adults With Type 1 Diabetes in Sweden

    Dec 1, 2025, 00:00

  • EE66 Assessing Treatment Efficiency Indicated in Rare Diseases: Learning From the CEESP Has Economic Opinions

    Dec 1, 2025, 00:00

  • RWD139 Quality and Impact of Real-World Data in Chronic Disease Research: Insights From Retrospective Studies Using the Hospital Episode Statistics (HES) Database

    Dec 1, 2025, 00:00

  • HTA87 Comprehensive Clinical Evaluation of Drugs for Moderate-to-Severe Chronic Obstructive Pulmonary Disease

    Dec 1, 2025, 00:00

  • MSR16 Advancing the Science of Qualitative Patient Preference Assessment Using Large Language Models

    Dec 1, 2025, 00:00

  • EE496 Healthcare and Economic Burden of Intravenous and Subcutaneous Immunoglobulin Treatment in Three Autoimmune Neuromuscular Diseases: A Bicentric Spanish Experience

    Dec 1, 2025, 00:00

  • CO96 Efficacy of Pregabalin and High-Concentration (179 mg) Capsaicin Patch in Peripheral Neuropathic Pain: A Review of Studies ≥ 26 Weeks' Duration

    Dec 1, 2025, 00:00

  • EPH210 Sedative-Hypnotic Drug Use and Polypharmacy Patterns Associated With Risk of Falls and Fractures in Older Adults by Osteoporosis Status: A Korean Nationwide Senior Cohort Study

    Dec 1, 2025, 00:00

  • HTA118 Early Health Technology Assessment and Cost-Effectiveness of the National Cardiovascular Disease Prevention Program in Greece

    Dec 1, 2025, 00:00

  • HTA151 From French Early Access to Regular Reimbursement: How Do Prices Shift Post-HTA?

    Dec 1, 2025, 00:00

  • EE164 Cost-Effectiveness Analysis of Tenecteplase vs. Alteplase for Adults With Acute Ischemic Stroke (AIS) in Greece

    Dec 1, 2025, 00:00

  • CO62 Comparison of Persistence Rates: Tildrakizumab vs. Adalimumab/Ustekinumab Based on a German Longitudinal Prescription Database (LRx) of Social Health Insurance Patients in Outpatient Care

    Dec 1, 2025, 00:00

  • HPR59 Divergent Biologic Price Archetypes: Year-on-Year List Price Evolution Pre- and Post-Biosimilar Entry in the US, Europe, and Japan

    Dec 1, 2025, 00:00

  • HTA73 Challenges in the German AMNOG Procedure: The Need for National PICO Transparency and Optimized Consultation Windows in the Context of EU-HTA

    Dec 1, 2025, 00:00

  • EE163 Cost-Effectiveness Analysis of Ribociclib With Endocrine Therapy for Treatment With Premenopausal Women With HR Positive HER2 Negative Early Breast Cancer in the UK

    Dec 1, 2025, 00:00

  • MT12 Cost Impact of the Porcine Urinary Bladder Matrix in Patients With Diabetic Foot Ulcer in the United Kingdom

    Dec 1, 2025, 00:00

  • RWD138 Primary Expenditure Drivers and Future Challenges From Emerging Technologies in Brazilian Private Market Real-World Data Analysis From a Brazilian Employer-Sponsored, Self-Insured Health Plan

    Dec 1, 2025, 00:00

  • PCR162 Multinational Qualitative Testing of the Experimental EuroQol Toddler and Infant Populations (EQ-TIPS) Instrument

    Dec 1, 2025, 00:00

  • HTA275 Provisional Listing of Digital Healthcare Applications Digas Improves Patients' Access to Healthcare in Germany

    Dec 1, 2025, 00:00

  • PCR15 An Initiative to Improve Patient Organization Engagement at the National Center for Pharmacoeconomics, Ireland

    Dec 1, 2025, 00:00

  • EE349 Economic and Antibiotic Benefits of Vonoprazan-Based Regimens for First-Line Helicobacter Pylori Eradication in China

    Dec 1, 2025, 00:00

  • HPR177 Review of Rare Disease Policy Developments in Europe and Türkiye 2020-2025 in the Context of Innovative Orphan Drugs

    Dec 1, 2025, 00:00

  • RWD141 Real-World Evidence Study on the Resource Impact of Subcutaneous vs. Intravenous Atezolizumab in an NHS Cancer Center

    Dec 1, 2025, 00:00

  • MSR167 Piloting a GenAI Agent for Structured Quality Appraisal of Network Meta-Analyses Using the ISPOR-AMCP-NPC Checklist

    Dec 1, 2025, 00:00

  • HTA144 Exploring Evidence Gaps in National Institute for Health and Care Excellence Early Value Assessments

    Dec 1, 2025, 00:00

  • MSR106 extRpolateS: A Shiny-Based Interactive Platform for Time-to-Event Data Modeling in Health Technology Assessments

    Dec 1, 2025, 00:00

  • RWD26 Burden of Duchenne Muscular Dystrophy in Italy: A Multicenter Cost of Illness Study

    Dec 1, 2025, 00:00

  • HPR205 The Implementation of the European Charter of Patients’ Rights in Hungarian and Romanian Healthcare Legislation With Special Emphasis on Informed Consent

    Dec 1, 2025, 00:00

  • EE139 Comparative Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole for the Treatment of Invasive Aspergillosis in Algerian Hospital Setting

    Dec 1, 2025, 00:00

  • SA70 Modeling the Lifetime Effects of Lecanemab in Early Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • HPR151 Optimizing Healthcare Systems in the MENA Region: Insights From Tailored Reimbursement for Innovative and Generic Essential Remedies (TRIGER) Meetings in Saudi Arabia and Algeria

    Dec 1, 2025, 00:00

  • HPR82 Evolution of Negotiations and Contracts for Reimbursement of Pharmaceuticals in Greece Between 2020 and 2025: Onwards and Upwards

    Dec 1, 2025, 00:00

  • PCR79 Evaluating GenAI vs. Human Screenshot Review Outputs in eCOA Localization: Does AI Hold the Key to Improved Feedback?

    Dec 1, 2025, 00:00

  • EE667 Socioeconomic Burden Among Children and Adults With Achondroplasia in Europe and Latin America

    Dec 1, 2025, 00:00

  • MSR28 Anchors Away: Navigating Unanchored Indirect Comparisons With Multilevel Unanchored Meta-Regression (ML-UMR)

    Dec 1, 2025, 00:00

  • CO255 Treatments for Children With Newly Diagnosed Medulloblastoma: A Systematic Review Of Randomized Controlled Trials

    Dec 1, 2025, 00:00

  • HPR17 Advancing INN-Based Prescribing in Saudi Arabia’s Private Sector: Implications for Biologics and Biosimilars Utilization Under CHI Oversight

    Dec 1, 2025, 00:00

  • HTA155 From License to Reimbursement: A Slot-Based ML Framework for Seamless MA to HTA Alignment

    Dec 1, 2025, 00:00

  • P4 Simulating Sponsor-HTA Conversations: A Multi-Agent GenAI Framework for Reimbursement Processes

    Dec 1, 2025, 00:00

  • CO167 Multimorbidity and Health-Related Quality of Life Among Adult Population in the United States

    Dec 1, 2025, 00:00

  • MT19 From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment

    Dec 1, 2025, 00:00

  • EE609 Piloting Structured Expert Elicitation: An Exploratory Case Study of Practical Implementation

    Dec 1, 2025, 00:00

  • RWD166 Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care

    Dec 1, 2025, 00:00

  • EE501 Healthcare Costs of Mammography Screening and Breast Cancer Treatment: A Registry-Based Study From Norway

    Dec 1, 2025, 00:00

  • EPH208 Respiratory Syncytial Virus (RSV) Knowledge and Perceived RSV Risk Groups Amongst GP/PCPs and Specialists in APAC: A Cross-Sectional Knowledge Attitude and Practices Survey (RESVIKAP)

    Dec 1, 2025, 00:00

  • EPH124 Heatstroke Is Associated With an Increased Risk of Chronic Headache: A Retrospective Cohort Study in Germany

    Dec 1, 2025, 00:00

  • HSD43 Environmental Impact of Intravenous vs. Oral Chemotherapy in Fran A 1000-Patient Model-Based Assessment

    Dec 1, 2025, 00:00

  • HPR106 Gender-specific Drug Prices in Germany: A Comparative Analysis

    Dec 1, 2025, 00:00

  • EE293 Cost-Savings Assessment of Fitusiran Prophylaxis in Minimizing Breakthrough Bleeding Treatment Expenses in the United Arab Emirates

    Dec 1, 2025, 00:00

  • SA12 An Interactive Tool to Select Indirect Treatment Comparison Methods for Rapid Feasibility Assessment

    Dec 1, 2025, 00:00

  • HTA362 What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques

    Dec 1, 2025, 00:00

  • CO44 Clinical Effectiveness and Safety of Second-Line Therapies for Immune Thrombocytopenia (ITP): A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HPR29 Assessing Stakeholders’ Perceptions of the EU Health Technology Assessment Regulation and Access to Innovative Medicines in Europe and the Netherlands: Challenges, Opportunities, and Recommendations

    Dec 1, 2025, 00:00

  • EE152 Considerations for Modeling Caregiver Spillover Within Economic Evaluations for Neurological Disorders: Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD), and Multiple Sclerosis (MS)

    Dec 1, 2025, 00:00

  • HPR86 Exploring Off-Label Drug Coding Trends in French Hospitals: A Descriptive and Stratified Analysis 2020-2024

    Dec 1, 2025, 00:00

  • SA5 A Systematic Literature Review on Economic Evaluations and Cost-Effectiveness of Second-Line Treatment Options for Immune Thrombocytopenia

    Dec 1, 2025, 00:00

  • EE2 A Budget Impact Analysis of Exclusive Human Milk Diet in Very Low Birth Weight Infants in Sheikh Shakhbout Medical City

    Dec 1, 2025, 00:00

  • HTA318 The HTA Landscape of Orphan Products in the UK Between 2019 and 2024

    Dec 1, 2025, 00:00

  • MSR161 Overfitting Mitigation in Neural Networks: Could Ergodic Regularization Be the Future of AI?

    Dec 1, 2025, 00:00

  • HPR35 Benefits and Challenges in the Implementation of EU HTAR for Medical Devices: Lessons Learned From the Pharmaceutical Industry

    Dec 1, 2025, 00:00

  • CO244 The Incidence and Economic Impact of Major Adverse Events Associated With Intravascular Temperature Management: A Systematic Review, Analysis, and Model

    Dec 1, 2025, 00:00

  • HPR96 Fit-for-Purpose Real-World Data: Lessons From FDA QCARD and EMA Data Quality Framework

    Dec 1, 2025, 00:00

  • EE143 Comparison of Nonstatin Lipid-Lowering Therapies (LLTs) by Their Annual Cost per Effectively Treated Very High-Risk Patient in Spain

    Dec 1, 2025, 00:00

  • HPR160 Physicians' and Pharmacists’ Views on Implementing Generic Medicines Standard and Biosimilar Guide

    Dec 1, 2025, 00:00

  • MSR183 ROBERTA on the Job: A Proof-of-Concept Study of a Customized GPT Tool for Risk-of-Bias Assessment of Randomized Clinical Trials

    Dec 1, 2025, 00:00

  • P32 The Healthcare Improvement Scotland Think Frailty Tool: A Preliminary Psychometric Evaluation

    Dec 1, 2025, 00:00

  • HPR210 The New Discount on Combination Drug Therapies in Germany: First Numbers and Assessment From a Payor Perspective

    Dec 1, 2025, 00:00

  • HPR155 Patient-Reported Outcomes Used for Regulatory Approval of Oncology Medicinal Products in the European Union Between 2021 and 2024: A Review Update

    Dec 1, 2025, 00:00

  • CO227 Systematic Literature Review and Bayesian Network Meta-Analysis of Sugemalimab Plus Chemotherapy vs. Other First-Line Treatments for Metastatic Non-Small Cell Lung Cancer Without Sensitizing eGFR, ALK, ROS1, or RET Alterations

    Dec 1, 2025, 00:00

  • HTA313 The Acceptability of Wearables in Remote Monitoring According to Health Technology Assessment HTA Bodies

    Dec 1, 2025, 00:00

  • CO20 Association Between ALK Tyrosine Kinase Inhibitor and the Risk of Interstitial Lung Disease and Pneumonitis in Non-Small Cell Lung Cancer Patients: A Systematic Review

    Dec 1, 2025, 00:00

  • MSR41 Assessing the Psychometric Performance of the Experimental EQ-TIPS V20 in Assessing the Health-Related Quality of Life of Stunted Children in Laos

    Dec 1, 2025, 00:00

  • HTA285 Reimbursement Trends Across Global Markets in 2024

    Dec 1, 2025, 00:00

  • PCR176 Patient Perspectives on Unmet Needs in mCRPC: Emphasizing Improved Quality of Life and Delay in Chemotherapy

    Dec 1, 2025, 00:00

  • EPH206 Real-World Uptake of SGLT2i Usage in Patients With Chronic Kidney Disease or Heart Failure: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • HTA38 Are Real-World Survival Outcomes in Metastatic Breast Cancer Transportable Between the US and Austria?

    Dec 1, 2025, 00:00

  • HSD58 How Do Neurologists Perceive the Organization and Functioning of Care in Their Multiple Sclerosis Units?

    Dec 1, 2025, 00:00

  • EE443 Evaluating the Economic Value of First-Line (1L) Treatment Strategies for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Insights From the Portuguese Healthcare System

    Dec 1, 2025, 00:00

  • RWD178 Systematic Review of Effectiveness of SGLT2 Inhibitors in Patients With Type 2 Diabetes With Focus on Glucose Levels, Cardiovascular Events, and Renal Function

    Dec 1, 2025, 00:00

  • EPH85 Estimating Rare Disease Incidence and Prevalence of Essential Thrombocythemia in Major Health Plans in the United States

    Dec 1, 2025, 00:00

  • EPH73 Epidemiological Analysis of Colorectal Cancer in Cyprus Amidst the Absence of Organized Screening Programs Data From 2000 to 2020

    Dec 1, 2025, 00:00

  • RWD37 Comorbidities As a Risk Predictor of Kidney Disease Progression Among Patients Diagnosed With Chronic Kidney Disease

    Dec 1, 2025, 00:00

  • EPH122 Healthcare Resource Use in Uncontrolled Hypertension: An Observational Study in England Using Electronic Health Records

    Dec 1, 2025, 00:00

  • RWD125 Millennial Medical Record (MMR) Data Profile: A Japanese Electronic Medical Records (EMRs) Database Utilizing Unstructured Data for Lung Cancer Research

    Dec 1, 2025, 00:00

  • RWD88 Gender Inequalities in Aortic and Mitral Valve Interventions in Sweden

    Dec 1, 2025, 00:00

  • RWD179 The Burden and Management of Flares Among Pregnant Patients With Generalized Pustular Psoriasis (GPP): Real-World Evidence (RWE) From the Global SCRIPTOR Study

    Dec 1, 2025, 00:00

  • RWD147 Real-World Assessment Process to Identify Fit-for-Purpose Data Sources to Meet Milestones for Post-Marketing Requirements (PMR), Post Authorization Safety Studies (PASS), and Health Technology Assessment (HTA) Submissions Utilizing S ...

    Dec 1, 2025, 00:00

  • PCR129 Impact of Glucagon-Like Peptide-1 Treatments on Patient-Reported Outcomes in Type 2 Diabetes Mellitus

    Dec 1, 2025, 00:00

  • HTA27 Advocating From the Margins: How Patient Input Aligns With Broader Evidence Tolerance in HTA Within Oncology

    Dec 1, 2025, 00:00

  • EPH141 Incidence and Treatment of Squamous-Cell Anal Cancer (SCAC) in Germany: A Retrospective Study in German Statutory Health Insurance (SHI) Claims Data

    Dec 1, 2025, 00:00

  • CO40 Characterization of the Distribution of Body Mass Index in Portuguese People With Type 2 Diabetes

    Dec 1, 2025, 00:00

  • EE440 Evaluating the Economic Benefit of Improved High-Dose Influenza Vaccine Coverage in the Elderly Population of Tokyo, Japan

    Dec 1, 2025, 00:00

  • EE11 A Cost-Effectiveness Analysis of Ustekinumab Against Vedolizumab Among Inflammatory Bowel Disease Patients With Extra-intestinal Manifestations in Egypt

    Dec 1, 2025, 00:00

  • HTA10 A New Approach for Modeling the Complexity of the Impact of Caring Using the Family and Caregiving Effects

    Dec 1, 2025, 00:00

  • EPH193 Prevalence of Post-Traumatic Stress Disorder Among Ambulance Officers During the COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • EE573 Markov Model-Based Cost-Effectiveness Evaluation of ROSA® vs. Manual Total Knee Arthroplasty: Sweden Payer Perspective

    Dec 1, 2025, 00:00

  • EE485 HDX vs. HDF in End-Stage Kidney Disease: Cost-Minimization Study in Saudi Arabia

    Dec 1, 2025, 00:00

  • PT19 Can Estimands Support Aligned Evidence Generation for EU HTA? Reflections on Their Role in Joint Clinical Assessments, PICO Alignment, and Beyond

    Dec 1, 2025, 00:00

  • HPR34 Barriers and Policy Solutions in Off-Patent Drug Repurposing: A Full-Life-Cycle Perspective

    Dec 1, 2025, 00:00

  • CO48 Clinical Outcomes Associated With Pembrolizumab Immunotherapy in Mesothelioma: A Systematic Review

    Dec 1, 2025, 00:00

  • EPH176 Persistence With Antidementia Therapy in Germany: A Retrospective Cohort Study of 212,850 Patients

    Dec 1, 2025, 00:00

  • RWD168 Risk of Abdominal Hernia Repair in Patients With Intestinal Stoma in Italy: A Real-World Analysis

    Dec 1, 2025, 00:00

  • CO41 Children With Asthma Receiving Dupilumab Plus Medium-Dose Inhaled Corticosteroids Had Improved Exacerbations, Lung Function, and Airway Inflammation Compared To Those Receiving Placebo Plus High-Dose Inhaled Corticosteroids

    Dec 1, 2025, 00:00

  • EE648 Repeated Breast Surgery After a Lumpectomy in England

    Dec 1, 2025, 00:00

  • PCR244 The Use of Patient-Reported Experience Measures in Adults With Obstructive Sleep Apnea: A Systematic Evidence Review

    Dec 1, 2025, 00:00

  • EE229 Cost-Effectiveness Evaluation of Combined Cervical Cancer Screening With CINtec PLUS in the Czech Republic

    Dec 1, 2025, 00:00

  • PCR133 Impact of Transfusion-Dependent Thalassemia on Adult Patients’ Health-Related Quality of Life and Work Productivity in the Kingdom of Saudi Arabia and United Arab Emirates

    Dec 1, 2025, 00:00

  • RWD93 Healthcare Resource Utilization Before and After Cardiovascular Disease Diagnosis in the NHS: A Descriptive Cohort Study

    Dec 1, 2025, 00:00

  • MSR219 Variations in Mortality Across Clinical Trials: A Review of Statistical Methods for Adjusting for the Effect of the COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • EE195 Cost-Effectiveness Analysis of CYP2C19 Genotype-Guided Antiplatelet Therapy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in the Netherlands

    Dec 1, 2025, 00:00

  • EE173 Cost-Effectiveness of WIC Eligibility Extension in Preventing Maternal Postpartum Depression: US Payers’ Perspective

    Dec 1, 2025, 00:00

  • HTA349 Use of AI Methods in NICE Technology Appraisals: What Is the Current Status Quo?

    Dec 1, 2025, 00:00

  • HPR195 The Czech Republic’s Dedicated Orphan Drug Reimbursement Mechanism 2022-2025: Improvements in Access

    Dec 1, 2025, 00:00

  • MSR207 Turning the Tables: AI Halves Table Extraction Time in HEOR Systematic Reviews

    Dec 1, 2025, 00:00

  • EE227 Cost-Effectiveness as Part of the German AMNOG Process Analyzing the 2025 SVR Proposal and Its Implementation Challenges

    Dec 1, 2025, 00:00

  • EE559 Intra-Procedure Cost Variability: A Retrospective Analysis of Real-World Patient Level Information Costing (PLICS) Data for a Minimally Invasive BPO Therapy in the NHS

    Dec 1, 2025, 00:00

  • MSR162 PACE in Scotland: Utilizing Machine Learning to Assess the Importance of Patient and Clinician Engagement in HTAs in SMC

    Dec 1, 2025, 00:00

  • EE18 A Health Economic Evaluation Framework for Implementing a Digital Survivorship Passport for Childhood Cancer Survivors

    Dec 1, 2025, 00:00

  • HTA268 Patient-Centered PICO Scoping in EU HTA: A Pilot Study for Structured Consensus Building Using a Delphi Panel

    Dec 1, 2025, 00:00

  • CO35 Burden of Illness Among Patients With Transfusion Dependent Beta-Thalassemia in Spain: A Registry-Based Study

    Dec 1, 2025, 00:00

  • CO207 Real-World Outcomes and Economic Impact of Ribociclib in HR+/HER2- Advanced Breast Cancer: Evidence From the Portuguese REASSURE Cohort

    Dec 1, 2025, 00:00

  • HPR235 Utilization of Glucagon-Like Peptide-1 Receptor Agonists in the Irish Healthcare System

    Dec 1, 2025, 00:00

  • EPH275 Urinary Dysfunction Management in Multiple Sclerosis: A Nationwide Real-Life Analysis From the French SNDS Database

    Dec 1, 2025, 00:00

  • RWD149 Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data

    Dec 1, 2025, 00:00

  • OP20 Qualitative Insights Into Artificial Intelligence (AI) and Virtual Reality (VR) Training for Value Communication: Comparing Innovative Technologies With Traditional Methods in Pharma

    Dec 1, 2025, 00:00

  • EPH2 A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine From Lower-Valent Vaccines in the French Pediatric Population

    Dec 1, 2025, 00:00

  • PT38 Efficacy and Safety of Nalbuphine Compared With Analgesics for Moderate to Severe Postoperative Pain: A Systematic Review and Network Meta-Analysis

    Dec 1, 2025, 00:00

  • PCR229 The Effects of Disease Modifying Anti-Rheumatic Drugs (DMARDs) on Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Network Meta-Analyses

    Dec 1, 2025, 00:00

  • HTA119 Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical Assessments

    Dec 1, 2025, 00:00

  • EE304 Cost-Utility Analysis of Linzagolix 200 mg Plus Add-back Therapy (Linzagolix+ABT) for Symptomatic Treatment of Endometriosis

    Dec 1, 2025, 00:00

  • EE148 Components of the Direct Cost of Topical Treatment for Chronic Wounds in Adults and Elderly: A Systematic Review

    Dec 1, 2025, 00:00

  • EE481 Global Economic Burden of Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EPH120 Healthcare Pathway of a Large Cohort of Patients With Chronic Obstructive Pulmonary Disease During the Last Year of Life

    Dec 1, 2025, 00:00

  • CO9 An Adjusted Indirect Comparison of Once-Weekly Insulin Efsitora Alfa vs. Insulin Icodec for Adults With Type 2 Diabetes Mellitus Previously Treated With Basal-Bolus Insulin

    Dec 1, 2025, 00:00

  • EE200 Cost-Effectiveness Analysis of FreeStyle Libre Systems vs. Self-Monitoring of Blood Glucose in People With Type 2 Diabetes on Basal Insulin: An Israeli Healthcare System Perspective

    Dec 1, 2025, 00:00

  • HPR209 The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways

    Dec 1, 2025, 00:00

  • HSD17 Burden of Healthcare Waste for European Hospitals: Findings From an AI-Based Literature Research

    Dec 1, 2025, 00:00

  • EE112 Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in France

    Dec 1, 2025, 00:00

  • EE317 Danicopan in Addition to the Component 5 Inhibitor C5i Ravulizumab for the Treatment of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Residual Hemolytic Anemia in Gree A Cost Utility Analysis

    Dec 1, 2025, 00:00

  • CO2 A Systematic Literature Review and Meta-Analysis Comparing Robotic-Assisted Mitral Valve Repair Using the Da Vinci Surgical System to Open Mitral Valve Repair

    Dec 1, 2025, 00:00

  • EE298 Cost-Utility Analysis of Add-On Vericiguat to Standard Treatment in Thai Patients With Heart Failure and Reduced Ejection Fraction

    Dec 1, 2025, 00:00

  • RWD155 Real-World Evidence of Atezolizumab in Unresectable Recurrent NSCLC: Insights From Japan's Next-Generation Medical Infrastructure Act

    Dec 1, 2025, 00:00

  • EE46 An Economic Evaluation of Risankizumab vs. Adalimumab in Moderate to Severe Plaque Psoriasis Adult Patients in Egypt

    Dec 1, 2025, 00:00

  • HTA105 Determinants of Willingness to Pay Thresholds in NICE Oncology Technology Appraisals

    Dec 1, 2025, 00:00

  • EPH280 Years of Life Lost and Productivity TB1 SY2 Costs Due to Premature Cancer-Related Mortality in Morocco

    Dec 1, 2025, 00:00

  • EPH224 Survival Trends in Multiple Myeloma by Treatment Era in the United States

    Dec 1, 2025, 00:00

  • EE35 A Systematic Review of the Methods and Quality of Economic Evaluations for AI-Assisted Cancer Screening or Diagnosis

    Dec 1, 2025, 00:00

  • HPR75 Evaluating the Costs and Benefits of Innovative Pricing and Payment Models in Europe

    Dec 1, 2025, 00:00

  • EE502 Healthcare Expenditure for Treatment of Cardiovascular Disease Among Hypercholesterolemia Patients in Japan: A Claims Data Analysis

    Dec 1, 2025, 00:00

  • HPR149 Negotiated Closed Budgets in Gree A Case Study of Success in Enhancing Patient Access Whilst Achieving Savings

    Dec 1, 2025, 00:00

  • PCR247 Treatment Discontinuation in Idiopathic Pulmonary Fibrosis: A Systematic Review of Antifibrotic Drug Use and Tolerability

    Dec 1, 2025, 00:00

  • P44 Early Economic Modeling to Estimate Cost-Effectiveness and Value-Based Price of a Gene Therapy for Urofacial Syndrome

    Dec 1, 2025, 00:00

  • HPR45 Clinical Outcome Assessments in Drug Approvals: Trends and Insights From FDA; EMA Labeling 2018-2023

    Dec 1, 2025, 00:00

  • PCR148 Listening to the Voice of the Patient: Insights From a Survey on the Burden of Recurrent Respiratory Papillomatosis in the United States

    Dec 1, 2025, 00:00

  • PT30 An Exploration of Implementing Herd Immunity Into Static Models for Economic Evaluation of Vaccines

    Dec 1, 2025, 00:00

  • MSR58 Comparing Individualized Treatment Effect Inference Methods Through a Simulation Study

    Dec 1, 2025, 00:00

  • EE545 Impacts of National Medical Insurance Negotiation on Antitumor Drug Utilization and Financial Burden: A City-Level Analysis in China

    Dec 1, 2025, 00:00

  • CO120 Extending Survival in Glioblastoma: Real-World Evidence of Post-Progression Benefit From Tumor-Treating Fields Therapy

    Dec 1, 2025, 00:00

  • EE585 Modeling the Clinical and Economic Impact of DPP-4 Inhibitors in Uncontrolled T2D

    Dec 1, 2025, 00:00

  • HTA148 Fractional Polynomial Survival Models in HTA: An Exploratory Review of Use and Methodological Guidance Across Global Agencies

    Dec 1, 2025, 00:00

  • EE41 Adjuvanted RSVpreF3 Vaccine for Respiratory Syncytial Virus Prevention in the United Kingdom, Spain, and Australia: A Climate Change Impact Analysis

    Dec 1, 2025, 00:00

  • EPH196 Public Health and Economic Impact of RSVpreF Maternal Vaccination Among Infants in Five Asian Countries

    Dec 1, 2025, 00:00

  • MT19 From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment

    Dec 1, 2025, 00:00

  • EE680 System-Level Economic Impact of a Combination Influenza-COVID-19 Vaccine vs. Standalone Vaccinations in the United Kingdom

    Dec 1, 2025, 00:00

  • EPH104 Exploring Factors Associated With Online Food Delivery Behavior Among Young Adults

    Dec 1, 2025, 00:00

  • PCR200 Qualitative Trial Interviews to Explore the Experience of Adult and Pediatric Patients Participating in a Pivotal Phase 3 Trial of DTX401 for Glycogen Storage Disease Type Ia

    Dec 1, 2025, 00:00

  • CO42 Clinical and Economic Outcomes of Cannabis-Based Formulations (CBD and CBD/CBG) for Autism Spectrum Disorder (ASD): A HEOR Model Study Analysis

    Dec 1, 2025, 00:00

  • HPR12 Accelerating Therapeutic Innovation: Early Results From France’s Accès Direct Scheme

    Dec 1, 2025, 00:00

  • PCR203 Quality-Adjusted Time Without Symptoms or Toxicity Q-TWiST Estimates in Previously Treated HER2-Positive Biliary Tract Carcinoma (BTC) Using the Zanidatamab HERIZON-BTC-01 Study

    Dec 1, 2025, 00:00

  • EE723 The Societal Value of Lecanemab for Patients With Early Alzheimer's Disease in Japan

    Dec 1, 2025, 00:00

  • HSD14 Biologic Treatment Patterns and Phenotyping in Severe Uncontrolled Asthma: A Multinational Study

    Dec 1, 2025, 00:00

  • MSR83 Eliciting Patients' and Clinicians' Preferences on Adjuvant Treatment for HR+/HER2- Early Breast Cancer: Design of a Probabilistic Threshold Technique in Italy

    Dec 1, 2025, 00:00

  • MSR59 Comparing Key European HTA Body Methodological Standards for Systematic Reviews of Economic and Utility Evidence

    Dec 1, 2025, 00:00

  • EE626 Quantifying the Economic Impact of Flexible Endoscope-Related Procedure Rescheduling in NHS Endoscopy Services: A Retrospective Analysis and Survey-Based Model

    Dec 1, 2025, 00:00

  • EE553 Informing the Sustainable Development of Novel Therapies Using Value-Based Real Options Analysis

    Dec 1, 2025, 00:00

  • MSR186 Simulated Treatment Comparisons Using Jackknife Pseudo Values for Population-Adjusted Marginal Effect Estimation

    Dec 1, 2025, 00:00

  • HPR66 Early Impact of the Mazars Review on Reimbursement Timelines in Ireland

    Dec 1, 2025, 00:00

  • EE623 Public Health Impact of Efluelda, a High-Dose Trivalent Influenza Vaccine (TIV-HD) Compared to Standard-Dose Trivalent Inactivated Vaccines (TIV-SD)

    Dec 1, 2025, 00:00

  • CO148 Incidence of Treatment-Related Adverse Events From Immune Checkpoint Inhibitors: A Meta-Analysis of Randomized Clinical Trials

    Dec 1, 2025, 00:00

  • HTA283 Reference Framework, Key Decision-Making Factors, and the Impact of Critical Parameters on Listing Recommendations for Nononcologic Drugs for Rare Diseases Issued by Canadian HTA Bodies

    Dec 1, 2025, 00:00

  • HPR233 Using Expert Consensus to Expand Access in Rare Disease Populations: Generating Evidence for Patients With Permanently Ventilated Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • EE199 Cost-Effectiveness Analysis of Follow-up Strategies for Localized or Locally Advanced Renal Cell Carcinoma From the UK NHS Perspective

    Dec 1, 2025, 00:00

  • SA103 What Makes a Medicine Innovative? A Literature Review of Evaluation Frameworks

    Dec 1, 2025, 00:00

  • PCR37 Capturing the Realities of Hematological Cancer Patients’ Experiences of Novel Immunotherapies: A Call for Alignment and Action to Improve PROM Within CAR-T and Bispecific Antibody Therapies

    Dec 1, 2025, 00:00

  • EPH136 Impact of RSV Infection on Acute Otitis Media Burden in Young Children Beyond Their First Year of Life in Japan

    Dec 1, 2025, 00:00

  • HPR219 Timing Matters: Missed Opportunity to Prevent RSV Cases in Older Adults in Germany: A Markov Model Analysis

    Dec 1, 2025, 00:00

  • HTA309 Systematic Review of Value Assessment Frameworks for Digital Health Interventions: Toward a Multidimensional Evaluation Approach

    Dec 1, 2025, 00:00

  • EPH70 Effects of Antidepressant Drug Classes on Dementia Risk: A 23-Year Cohort Study Using Akrivia Health Secondary Mental Health Data

    Dec 1, 2025, 00:00

  • P60 The Social Impact of Health (SIoH) Framework: Capturing How Health-Driven Productivity Shapes National Development

    Dec 1, 2025, 00:00

  • MSR223 When Excel Starts Talking Back: Unlocking the Power of Conversational AI for Health Economic Models

    Dec 1, 2025, 00:00

  • EE299 Cost-Utility Analysis of AI-Assisted Ultrasound for Breast Cancer Detection in Taiwan

    Dec 1, 2025, 00:00

  • MSR105 Exploring Perspectives on Adult Pneumococcal Vaccination: A Qualitative Preference Study of Healthcare Providers (HCPs) and Healthcare Consumers (HCCs) in the United Kingdom and Italy

    Dec 1, 2025, 00:00

  • HPR224 Trends and Scope of Japan’s Across-the-Board Pharmaceutical Price Revisions in FY2021-25

    Dec 1, 2025, 00:00

  • P8 Assessing the Full Life-Cycle Value of Highly Specialized Technologies and Advanced Therapy Medicinal Products in England

    Dec 1, 2025, 00:00

  • HTA71 Challenges in PICO Definition for HTDs: Lessons From Durvalumab Exercise

    Dec 1, 2025, 00:00

  • HTA36 Application of Budget Impact Model in Evaluation of P2P Payment Strategy in US Health Systems

    Dec 1, 2025, 00:00

  • EPH78 Epidemiology and Demographic Characteristics of Phenylketonuria in Brazil: A Real-World Data Study (2019-2024)

    Dec 1, 2025, 00:00

  • MSR171 Prediction of Query Outcomes in the Setting of Observational Studies

    Dec 1, 2025, 00:00

  • HPR142 Mind the Gap: Exploring Variation in Guidelines for Indirect Treatment Comparison (ITC) Across Europe

    Dec 1, 2025, 00:00

  • EE583 Model Structure Variability in NICE HTAs: Evidence From Asthma and TMA Appraisals to Support the Need for Disease-Specific Reference Models

    Dec 1, 2025, 00:00

  • SA26 Current Use of Hereditary Angioedema (HAE) Treatments in Sweden: An Analysis of the National Prescribed Drug Register

    Dec 1, 2025, 00:00

  • HTA25 Advancing a Greener Ecosystem in Health Technology Assessment: A Review of Environmental Integration as an Additional Value Driver

    Dec 1, 2025, 00:00

  • HSD18 Burden of In-Clinic and At-Home Administration of Injectable Biologics for Severe Asthma and Chronic Rhinosinusitis With Nasal Polyps: Interim Results From a Time and Motion Study

    Dec 1, 2025, 00:00

  • HTA254 NICE Has Embraced Single-Arm Trials in Technology Appraisals but Where Is the Guidance?

    Dec 1, 2025, 00:00

  • RWD117 Leveraging Large Language Models and EMR Data to Identify Undiagnosed Rare Diseases: A Hybrid AI Approach

    Dec 1, 2025, 00:00

  • EPH276 Utility Values for Dementia in Finland and Spain

    Dec 1, 2025, 00:00

  • SA38 Enhancing Targeted Literature Reviews (TLRs) with Artificial Intelligence (AI): A Methodological Approach for Conducting Efficient Targeted Searches

    Dec 1, 2025, 00:00

  • PCR207 Real-World Socioeconomic Burden and Health-Related Quality of Life (HRQoL) for Patients Living with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the UK: Results From an Online Patient Survey

    Dec 1, 2025, 00:00

  • HTA172 Health Technologies Using Artificial Intelligen What Is Being Assessed in the UK by NICE?

    Dec 1, 2025, 00:00

  • P6 Potential Modifiers of Cost-Effectiveness Thresholds: Public Perspectives on Prioritization in Healthcare Spending

    Dec 1, 2025, 00:00

  • HPR10 A Strategic National Framework for Managed Entry Agreements to Access Innovative and Breakthrough Medications in Saudi Arabia

    Dec 1, 2025, 00:00

  • PT33 Trends in Reimbursement Agreements for Innovative Orphan and Oncological Medicines in Spain 2020-2025

    Dec 1, 2025, 00:00

  • Disclosure Information

    Dec 1, 2025, 00:00

  • CO175 Overall Treatment Landscape of Mucosal Melanoma

    Dec 1, 2025, 00:00

  • EE423 Estimating the Broader Societal Impact of Ocrelizumab for Multiple Sclerosis (MS) in Latin America (LATAM) Using a Social Impact Approach

    Dec 1, 2025, 00:00

  • EPH156 Large Language Model (LLM) as Catalyst for Rapid and Efficient Critical Appraisal of Epidemiological Research

    Dec 1, 2025, 00:00

  • RWD65 Disease Management in Adults with Type 1 Diabetes Who Have a Prior Type 2 Diabetes Misdiagnosis and Recorded HbA1c in a US Managed Care Population

    Dec 1, 2025, 00:00

  • EPH240 The Health Impact of Pembrolizumab Plus Chemotherapy in the First-Line Treatment for Metastatic Triple-Negative Breast Cancer (TNBC) in Türkiye

    Dec 1, 2025, 00:00

  • EE738 Treatment With Semaglutide Reduces the Complication Costs Among Type 2 Diabetes Patients With CKD in China: A Short-Term Cost Analysis Based on the FLOW Trial

    Dec 1, 2025, 00:00

  • EE285 Costs and Health Outcomes of Meek Skin Micrografting vs. Mesh Skin Grafting in Adult Patients With Deep Partial Thickness and/or Full-Thickness Small (Burn) Wounds

    Dec 1, 2025, 00:00

  • MSR149 Modeling Price Premiums of Oncology Drugs in Germany: A Cross-Validated Analysis Using XGBoost

    Dec 1, 2025, 00:00

  • EPH113 Fostamatinib-Induced Hepatomegaly: A Novel Signal Identified Through US Food and Drug Administration Adverse Event Reporting System (FAERS) Database

    Dec 1, 2025, 00:00

  • HSD78 Optimizing Healthcare Access Through Policy Innovation: An Implementation Evaluation Framework for Hepatitis C Elimination Program in Malaysia

    Dec 1, 2025, 00:00

  • EE720 The Public Health and Economic Effects of Various RSV Vaccination Strategies With RSVpreF Among Adults in France

    Dec 1, 2025, 00:00

  • HTA95 Cost-Effectiveness Analysis of RSVpreF Vaccine for RSV Prevention in Older Adults Under Situation of the National Vaccination Program in Taiwan: A Study on Economic and Clinical Advantages

    Dec 1, 2025, 00:00

  • PCR139 Informing Health System Reform Through Patient Perspectives: Saudi Arabia’s OECD Paris Survey Results

    Dec 1, 2025, 00:00

  • RWD67 Disproportionality Analysis Of Vedolizumab to Identify a Putative Signal Using Real-World Postmarketing Surveillance Data Reported in the FAERS Database

    Dec 1, 2025, 00:00

  • MSR40 Assessing Known Groups and Convergent Validity of the EQ-5D-5L in Assessing the Health-Related Quality of Life of Individuals With Obesity Who Have and Have Not Received Bariatric Surgery

    Dec 1, 2025, 00:00

  • P58 An Evaluation Framework for Healthcare Professionals’ Digital Health and AI Technologies: Evidence-Based Policy Recommendations

    Dec 1, 2025, 00:00

  • EPH9 A Systematic Literature Review to Identify Potential Risk Factors and Causative Organisms for Neonatal Sepsis in Indian Neonates

    Dec 1, 2025, 00:00

  • EPH8 A Retrospective Study of Treatment Use in Metastatic Colorectal Cancer (mCRC) Based on French Hospital Discharge Database

    Dec 1, 2025, 00:00

  • EPH18 Are Anti-Obesity Drugs Life-Saving or Lifestyle Medicines? Reframing the Policy and Economic Debate

    Dec 1, 2025, 00:00

  • EPH84 Estimated Healthcare Resource Utilization and Costs Associated With Semaglutide Life Expectancy Gains in a Real-World Population With CVD and Overweight or Obesity in the United Kingdom

    Dec 1, 2025, 00:00

  • P54 Thus SPOKE the TA: Querying NICE Technology Assessments Using Generative AI and RAG

    Dec 1, 2025, 00:00

  • HTA243 Navigating HTA and Innovation: Oncologists’ Perspectives on Access to Cancer Therapies in Bulgaria

    Dec 1, 2025, 00:00

  • EPH131 Identifying CKD As a Key Driver of CVD Deaths

    Dec 1, 2025, 00:00

  • P14 Cost-Effectiveness Modeling of Test and Treat Strategies: A Diagnosis of Over-Complexity

    Dec 1, 2025, 00:00

  • HSD67 Knowledge and Practices Regarding Expired Medications Among Saudi Citizens

    Dec 1, 2025, 00:00

  • EE356 Economic Burden in Metastatic Triple-Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • PCR174 Patient Perspectives on Mild-Moderate Infection Burden in Multiple Myeloma and Chronic Lymphocytic/Small Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • PCR137 Improving Time to Patient: Insights From the Canadian Cancer Treatment Hackathons

    Dec 1, 2025, 00:00

  • MSR125 Human Alignment on Evaluating LLMs for Literature Review Extraction

    Dec 1, 2025, 00:00

  • EE656 Site of Care Cost-Effectiveness of Axicabtagene Ciloleucel in Relapsed/Refractory Second-Line or Later Large B-cell Lymphoma in the United States: Analyses for Inpatient and Outpatient Infusion Settings

    Dec 1, 2025, 00:00

  • HSD30 Current Treatment Pathway for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in England: Insights From a Qualitative Validation With Clinical Experts

    Dec 1, 2025, 00:00

  • CO61 Comparison of Bispecific T-cell Engager Antibodies and CAR-T Therapies for Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma: A Systematic Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • EE153 Constructing a Dynamic Budget Impact Model: An AI Pretraining Approach for a New Parkinson's Disease Drug

    Dec 1, 2025, 00:00

  • CO146 Improving Colorectal Cancer Surgical Outcomes Through Audit and Feedback: Results From the Emilia Romagna ESCA Program

    Dec 1, 2025, 00:00

  • EPH231 The Cost of Complacency: Projecting the Burden of HIV Care in Eight European Countries

    Dec 1, 2025, 00:00

  • HPR3 A Comparative Analysis of Early Access Pathways in Italy and Fran Law 64896 vs. the French AAP

    Dec 1, 2025, 00:00

  • EPH88 Estimating the Future Burden of Unvaccinated Girls Against Human Papilloma Virus (HPV) in Europe: A Modeling Study

    Dec 1, 2025, 00:00

  • MSR55 Clinically Informed, Cost-Sensitive Machine Learning for Predicting Hospital-Acquired Pressure Injuries: A Practical Approach Using Routinely Collected Data

    Dec 1, 2025, 00:00

  • EPH243 The Incidence and Survival of HPV-Positive and HPV-Negative Malignant Head and Neck Squamous Cell Carcinoma (HNSCC) in the United States: A Surveillance Epidemiology and End Results SEER 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • HPR20 An Analysis of Differences in Patient Access to CGRP Migraine Treatments in the Nordic Region

    Dec 1, 2025, 00:00

  • PT11 High Entry Costs Slower Growth: A Nationwide Register Study on Newly Reimbursed Biologic Medicines in Finland 2011-2021

    Dec 1, 2025, 00:00

  • EPH223 Survey of Depression Literacy and Help-Seeking Behavior Among Secondary School Students

    Dec 1, 2025, 00:00
  • 1 (current)
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »